JonesTrading raises Spyre Therapeutics target price to $130 from $121
SYRE•JonesTrading raised its target price for Spyre Therapeutics to $130 from $121.
Related News
Candel Therapeutics phase 2a NSCLC study shows 24.5-month median overall survival with aglatimagene plus valacyclovir after ICI failure
CADL•
Fervo rises after Cape Station starts power production ahead of schedule
FRVO•
Vertex appoints DataRobot CEO Debanjan Saha to board of directors
VERX•
PMGC launches NorthStrive SPAC sponsorship platform with $100 million NSAI IPO
ELAB•
HealthLynked selects DRCARE247 as telemedicine partner
HLYK•